Copyright
©The Author(s) 2021.
World J Psychiatr. Nov 19, 2021; 11(11): 1065-1074
Published online Nov 19, 2021. doi: 10.5498/wjp.v11.i11.1065
Published online Nov 19, 2021. doi: 10.5498/wjp.v11.i11.1065
Figure 1 Interleukin-33/suppressor of tumorigenicity 2 axis as a crossroad in schizophrenia-breast cancer comorbidity.
Higher serum levels of interleukin-33 (IL-33) have been measured in a psychotic episode of schizophrenia, and IL-33 is also significantly higher in serum and portends tumor recurrence in patients with breast cancer. IL-33: Interleukin-33.
Figure 2 Estrogen receptor modulators and antipsychotics in interleukin-33 targeting strategies.
A: Raloxifene could be tissue-specific and improve cognition. B: Tamoxifen resistance in breast carcinoma could be improved by antipsychotics targeting IL-33. IL-33: Interleukin-33.
- Citation: Borovcanin MM, Vesic K. Breast cancer in schizophrenia could be interleukin-33-mediated. World J Psychiatr 2021; 11(11): 1065-1074
- URL: https://www.wjgnet.com/2220-3206/full/v11/i11/1065.htm
- DOI: https://dx.doi.org/10.5498/wjp.v11.i11.1065